References

1. India State-Level Disease Burden Initiative Cancer Collaborators. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Oncol. 2018 Oct;19(10):1289–306.
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707–16.
3. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383(9935):2127–35.
4. Punglia RS, Saito AM, Neville BA, Earle CC, Weeks JC. Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. BMJ. 2010 Mar 2;340:c845.
5. Munshi A, Ganesh T, Mohanti BK. Radiotherapy in India: History, current scenario and proposed solutions. Indian J Cancer. 2019 Oct;56(4):359–63.
6. Lam J, Cook T, Foster S, Poon R, Milross C, Sundaresan P. Examining Determinants of Radiotherapy Access: Do Cost and Radiotherapy Inconvenience Affect Uptake of Breast-conserving Treatment for Early Breast Cancer? Clin Oncol . 2015 Aug;27(8):465–71.
7. Cohen L. Radiotherapy in breast cancer. I. The dose-time relationship theoretical considerations. Br J Radiol. 1952 Dec;25(300):636–42.
8. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005 Apr;75(1):9–17.
9. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006 Jun;7(6):467–71.
10. Whelan TJ, Pignol JP, Levine MN. Are Three Weeks of Whole-Breast Radiotherapy as Good as Five Weeks in Early Breast Cancer?–10 Year Follow-Up in the Canadian Trial of Hypofractionated …. Breast Care [Internet]. 2010; Available from: http://www.karger.com/Article/Abstract/319790
11. Haviland JS, Mannino M, Griffin C, Porta N, Sydenham M, Bliss JM, et al. Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol [Internet]. 2017 Nov 15; Available from: http://dx.doi.org/10.1016/j.radonc.2017.10.033
12. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Oct;14(11):1086–94.
13. Valle LF, Agarwal S, Bickel KE, Herchek HA, Nalepinski DC, Kapadia NS. Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2017 Apr;162(3):409–17.
14. Courdi A, Ortholan C, Hannoun-Lévi J-M, Ferrero J-M, Largillier R, Balu-Maestro C, et al. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol. 2006 May;79(2):156–61.
15. FAST Trialists group, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011 Jul;100(1):93–100.
16. Sanz J, Zhao M, Rodríguez N, Granado R, Foro P, Reig A, et al. Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients: Efficacy and Tolerance in 486 Patients. Biomed Res Int. 2018 Mar 15;2018:8321871.
17. Dragun AE, Ajkay NJ, Riley EC, Roberts TL, Pan J, Rai SN, et al. First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):595–602.
18. Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016 Jul;120(1):114–8.
19. Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):47–56.
20. Franco P, Zeverino M, Migliaccio F, Cante D, Sciacero P, Casanova Borca V, et al. Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol. 2014 Jan;140(1):167–77.
21. Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, et al. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol. 2012 Jun 1;7:80.
22. Mondal D, Julka PK, Sharma DN, Jana M, Laviraj MA, Deo SV, et al. Accelerated hypofractionated adjuvant whole breast radiation with simultaneous integrated boost using volumetric modulated arc therapy for early breast cancer: A phase I/II dosimetric and clinical feasibility study from a tertiary cancer care centre of India. J Egypt Natl Canc Inst. 2017 Mar;29(1):39–45.
23. Shin SM, No HS, Vega RM, Fenton-Kerimian M, Maisonet O, Hitchen C, et al. Breast, chest wall, and nodal irradiation with prone set-up: Results of a hypofractionated trial with a median follow-up of 35 months. Pract Radiat Oncol. 2016 Jul;6(4):e81–8.
24. De Rose F, Fogliata A, Franceschini D, Navarria P, Villa E, Iftode C, et al. Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. Radiat Oncol. 2016 Sep 17;11(1):120.
25. Cooper BT, Formenti-Ujlaki GF, Li X, Shin SM, Fenton-Kerimian M, Guth A, et al. Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed [Internet]. Vol. 95, International journal of radiation oncology, biology, physics. 2016. p. 571–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27131077
26. Cante D, Petrucci E, Sciacero P, Piva C, Ferrario S, Bagnera S, et al. Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer. Med Oncol. 2017 Sep;34(9):152.
27. Paelinck L, Gulyban A, Lakosi F, Vercauteren T, De Gersem W, Speleers B, et al. Does an integrated boost increase acute toxicity in prone hypofractionated breast irradiation? A randomized controlled trial. Radiother Oncol. 2017 Jan;122(1):30–6.
28. Versmessen H, Vinh-Hung V, Van Parijs H, Miedema G, Voordeckers M, Adriaenssens N, et al. Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy [Internet]. Vol. 12, BMC cancer. 2012. p. 495. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23098579
29. Coles CE, Griffin CL, Kirby AM, Haviland JS, Titley JC, Benstead K, et al. Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003) [Internet]. San Antonio Breast Cancer Symposium; 2018 Dec 6 [cited 2018 Nov 30]; San Antionio, Texas, USA. Available from: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_527&terms=
30. Mukesh MB, Duke S, Parashar D, Wishart G, Coles CE, Wilson C. The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection. Radiother Oncol. 2014 Mar;110(3):461–6.
31. Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10–8.
32. Yi SK, Hall WH, Mathai M, Dublin AB, Gupta V, Purdy JA, et al. Validating the RTOG-endorsed brachial plexus contouring atlas: an evaluation of reproducibility among patients treated by intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;82(3):1060–4.
33. START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008 Apr;9(4):331–41.
34. Kundu S, Chakraborty S, Chatterjee S, Das S, Achari RB, Mukhopadhyay J, et al. De-Identification of Radiomics Data Retaining Longitudinal Temporal Information. J Med Syst. 2020 Apr 2;44(5):99.
35. Brunt AM, Haviland J, Sydenham M, Algurafi H, Alhasso A, Bliss P, et al. FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). In: Annual Meeting of the American Society of Radiation Oncology. American Society of Radiation Oncology; 2018. p. 1603–4.